Discontinued drug projects in the respiratory therapeutic area during 2012

Bibliography

• Fajt M, Gelhaus S, Freeman B, et al. Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and Th2 inflammation. J Allergy Clin Immunol 2013;131:1504-12
   PubMed Web of Science ®Google Scholar
• Pettipher R, Whittaker M. Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis. J Med Chem 2012;55:2915-31
   PubMed Web of Science ®Google Scholar
• Diamant Z, Singh D, O'Connor BJ, et al. Effect of multiple-dose setipiprant, a selective oral CRTH2 antagonist, on allergen-induced airway responses in allergic asthmatic patients. Am J Respir Crit Care Med 2012;185:A3957
   Google Scholar
• Press release, Actelion. 2012. Available from: http://www.actelion.com/en/our-company/news-and-events/index.page?newsId=1598979) [Last accessed 24 November 2013]
   Google Scholar
• Company presentation, Roche. 2012. slide 68 Available from: http://www.roche.com/irp2q12e.pdf [Last accessed 24 November 2013]
   Google Scholar
• Snell N, Foster M, Vestbo J. Efficacy and safety of AZD1981, a CRTh2 receptor antagonist, in patients with moderate to severe COPD. Respir Med 2013;107:1722-30
   PubMed Web of Science ®Google Scholar
• Krenitsky V, Nadolny L, Delgado M, et al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 2012;22:1433-8
   PubMed Web of Science ®Google Scholar
• Kluwe J, Pradere J-P, Gwak G-Y, et al. Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition. Gastroenterology 2010;138:347-59
   PubMed Web of Science ®Google Scholar
• Flynn C, Cheung-Flynn J, Smoke C, et al. Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci 2010;99:3100-21
   PubMed Web of Science ®Google Scholar
• Pini A, Viappiani S, Calosi L, et al. Effects of NCX 226, a compound targeting endothelin receptors and NO pathway, on bleomycin-induced lung inflammation and fibrosis in the mouse. Ann Rheum Dis 2011;70(Suppl 3):490
   Google Scholar
• Struthers M, Pasternak A. CCR2 antagonists. Curr Top Med Chem 2010;10:1278-98
   PubMed Web of Science ®Google Scholar
• Available from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D3320C00002 [Last accessed 23 November 2013]
   Google Scholar
• Press release, Orexo. 2012. Pages 2 & 4 Available from: http://feed.ne.cision.com/wpyfs/00/00/00/00/00/18/0D/87/wkr0001.pdf [Last accessed 28 September 2013]
   Google Scholar
• Lam B. Leukotriene C4 synthase. Prostaglandins Leukot Essent Fatty Acids 2003;69:111-16
   PubMed Web of Science ®Google Scholar
• Cartwright H. AstraZeneca to evaluate orexo respiratory programme previously partnered with Janssen. Pharma Deals Review 2013(2):14
   Google Scholar
• Fuentes M, Ma X, Zhang J, et al. Anti-TSLPR antibody RG7258 blocks dendritic cell activation, mast cell cytokine release and reduces Th2 inflammation in a non-human primate model of allergic lung inflammation. Am J Respir Crit Care Med 2011;183:A2767
   Google Scholar
• Busse W, Wenzel S, Meltzer E, et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 2013;131:339-45
   PubMed Web of Science ®Google Scholar
• Hall I, Sarno M, Disse B, et al. Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid. Eur Respir J 2012;40(Suppl 56):312s
   Google Scholar
• Eberhardt C, Klopfenstein N, Larsen P, et al. ARRY-502, a potent and selective CRTh2 antagonist, affects basophil and eosinophil function both in vitro and in vivo. Am J Respir Crit Care Med 2011;183:A4353
   Google Scholar
• Experimental asthma drug meets main goal in mid-stage study. Medscape; Available from: www.medscape.com [Last accessed 23 July 2013]
   Google Scholar
• Singh D, Cadden P, Hunter M, et al. Inhibition of the asthmatic allergen challenge response by the CRTh2 antagonist OC000459. Eur Respir J 2013;41:46-52
   PubMed Web of Science ®Google Scholar
• Barnes N, Pavord I, Chuchalin A, et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 2012;42:38-48
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Whitmarsh M, Prosser J, et al. The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma. Eur Respir J 2013;42:137s
   Google Scholar
• Fitzgerald M, Snape S, Febbraro S, et al. The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects. Eur Respir J 2013;42:697s
   Google Scholar
• Wells A, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis; an alarming press release. Eur Respir J 2012;39:805-6
   PubMed Web of Science ®Google Scholar
• Carroll J. Novartis cropping 371 research jobs in global R&D shakeup. Available from: http://www.fiercebiotech.com/story/novartis-chopping-371-research-jobs-global-rd-reorganization/2013-11-05 [Last accessed 23 November 2013]
   Google Scholar
• Stockley R, Snell N, Donovan L, et al. Effects of AZD9056, a P2X7 antagonist, in patients with chronic obstructive pulmonary disease. Thorax 2008;63(Suppl VIII):A41-2
   PubMedGoogle Scholar
• Miao Z, Wang Y, Manmohan L, et al. The CCR4 antagonist CCX6239 for the treatment of allergic airways disease. Eur Respir J 2013;42:725s
   Google Scholar
• Pavord I, De Soyza A, Elborn J, et al. Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. Eur Respir J 2013;42:331s-2s
   Google Scholar
• Kilty I, Clarke N, Fairmain D, et al. PF-03715455: an inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease. Eur Respir J 2013;42:344s
   Google Scholar
• Macnee W, Allan R, Jones I, et al. Efficacy and safety of the oral p38 inhibitor PH-797804 in chronic obstructive pulmonary disease: a randomised clinical trial. Thorax 2013;68:738-45
   PubMed Web of Science ®Google Scholar
• Experimental asthma drug fails in mid-stage study. Medscape; Available from: www.medscape.com [Last accessed 26 August 2013]
   Google Scholar
• Compton C, McBryan D, Bucchioni E, Patalano F. The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2013;26:562-73
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66
   PubMed Web of Science ®Google Scholar
• Franciosi L, Diamant Z, Banner K, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013;1:714-27
   PubMed Web of Science ®Google Scholar